Sharpless reflects on his time at FDA: “The engine producing new cancer therapies and diagnostics is doing very well”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The progress in cancer exceeds that of any other therapeutic area right now—at least as far as FDA is concerned, NCI Director Ned Sharpless said at a Dec. 3 joint meeting of the Board of Scientific Advisors and the National Cancer Advisory Board.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

In this episode of The Cancer Letter Podcast, Fran Visco, president of the National Breast Cancer Coalition, and Jacquelyn Cobb, managing editor of The Cancer Letter, discuss the Metastatic Breast Cancer Act, bipartisan legislation that would eliminate the waiting periods for Social Security Disability Insurance and Medicare for eligible people with metastatic breast cancer. 
Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login